Nouscom AG

Nouscom AG

Headquarter
Basel, Switzerland

Milestones
Founded: 2015
Invested: 2024

Founders / CEO
Marina Udier, CEO

Vertical
Biotech

Board Participation
Paolo di Giorgio, Board Member

Website

Linkedin

 

 

Developer of an immunotherapy platform designed to develop engineered viral vector vaccines for the treatment of cancer. The company's platform utilizes a portfolio of engineered viral vectors optimized for the efficient expression of long strings of tumor neoantigens and comprises a toolkit for the induction of broad and potent antitumor T-cell responses, enabling patients to enhance cancer-specific cellular immunity.

 

Related news:

Nouscom Secures €75.8 Million Series C Investment Boost for Advancing Cancer Vaccine Development